1Hamlyn JM, Hamilton BP, Manunta P. Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis[J].J Hypertens,1996,14(2),151-167.
2Quadri L, Bianchi G, Cerri A, et al. 17beta-(3-furyl)-5beta-androstane-3beta, 14beta, 17beta-triol(PST2238):A very potent antihypertensive agent with a novel mechanism of action[J].J Med Chem,1997,40(11):1561-1564.
3Balzan S, Montali U, Di Bartolo V, et al. Further evidence for an endogenous digitalis-like compound in newborn and adult plasma detected by anti-ouabain antiserum[J].Life Sci, 1997,60(12):893-898.
4Qazzaz HMA, Goudy SL, Valdes R. Deglycosylated products of endogenous digoxin-like immunoreactive factor in mammalian tissue[J].J Bio Chem ,1996,271(15):8731-8737.
5Wright DA, Lord GA, White RW, et al. Evidence for circulating bufenolide in a volume-expanded patient[J].Lacent,1997,350(9075):409.
6Sich B, Kirch U, Tepel M, et al. Pulse pressure correlates in humans with a proscillaridin A immunoreactive compound[J].Hypertension,1996,27(5):1073-1078.
7Tao Q-F, Hollenberg NK, Price AP, et al. Sodium pump isoform specificity for the digitalis-like factor isolated from human peritoneal dialysate[J].Hypertension,1996,29(3):815-821.
8Krep HH, Price DA, Soszynski P, et al. Volume sensitive hypertension and the digoxin-like factor. Reversal by a Fab directed against digoxin in DOCA-Salt hypertension rats[J].Am J hypertens,1995,8(9):921-927.
9Zhu Z, Tepel M, Nuesser M, et al. Low concentrations of ouabain increase cytosolicfree calcium concentration in rat vascular smooth muscle cells[J].Clin Sci,1996,90(1):9-12.
10Goto A, Yamada K, Hazama H, et al. Ouabainlike compound in hypertension associated with ectopic corticotropin syndrome[J].Hypertension ,1996,28(3):421-425.
3[1]Goto A, Yamnada K. Putative roles of ouabainlike ompound in hypertension: Revisited. Hypertens Res,2000;23:7～13
4[3]Kaide J, Ura N, Torii T et al. Effects of digoxin-specific antibody Fab Fragment (Digibind) on blood pressure and renal water-sodium metabolism in 5/6 reduced renal mass hypertensive rats. Am J Hypertens,1999;12:611～19
5[5]Ferrari P, Torielli L, Ferrandi M et al. PST2238:A new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol Exp Ther,1998;285(1):83～94
6[8]Balzan S, Urso GD, Ghione S et al. Selective inhibition of human erythrocyte Na+/K+ ATPase by cardiac glycosides and by a mammalian digitalis like factor. Life Sciences, 2000;67( ):1921～8
7Ferrari P, Ferrandi M, Tripodi L, et al. PST2238: a new antihypertensive compound that modulates Na^+, K^+ - ATPase in genetic hypertension[J] .J Pharm Exp Ther, 1999, 288:1074-1083.
8Ian M, Phillips SM, Galli. The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease[ J ]. Drugs, 2000, 60 (2) : 239-248.
9Kendall M J, Toeseu V. The HOT Study. Hypertension Optimal Therapy[J], J Clin Pharm Ther, 1998, 23(2) : 137-139,.
10Schoner W.Endogenous cardiac glycosides.a new class ofsteroid hormones.Eur J Biochem 2002; 269(10):2440-2448.
